BG Medicine Announces Agreement with Boehringer Ingelheim Pharmaceuticals, Inc.

WALTHAM, Mass.--(BUSINESS WIRE)--July 28, 2005--BG Medicine announced today that it has entered into an agreement with Boehringer Ingelheim Pharmaceuticals, Inc. BG Medicine will apply its Systems Pharmacology platform to elucidate tissue drug effects and discover circulating biomarkers for clinical application. BG Medicine will take a systems biology approach employing multiple platforms to generate data for analyses in proprietary bioinformatics and statistical methods. Financial terms of the agreement were not disclosed.

"We are pleased to enter into this agreement with Boehringer Ingelheim Pharmaceuticals, Inc., a global leader in the pharmaceutical industry," said Pieter Muntendam, M.D., President of BG Medicine. "This combination of elucidation of drug mechanism and biomarker discovery illustrates how our integrated platform can be applied as an integral part of drug development."

“This combination of elucidation of drug mechanism and biomarker discovery illustrates how our integrated platform can be applied as an integral part of drug development.”

About BG Medicine

BG Medicine is pioneering the commercial application of Systems Pharmacology, which is based on scientific advances in the Systems Biology field. Its advanced proprietary platform enables novel paths to new medicines through molecular fingerprinting of genes, proteins, and metabolites combined with powerful bioinformatics integration to produce Systems Response Profiles(TM). These profiles, which combine information from multiple physiological compartments and often include thousands of distinct analyte levels, have enabled unprecedented molecular characterization of disease states and drug response. BG Medicine applies its novel approach through collaborations with leading pharmaceutical companies. For more information please visit www.bg-medicine.com.